Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A large-cohort, longitudinal study determines pre-cancer disease routes across different cancer types

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Human papillomavirus vaccination in immigrants and descendants of immigrants in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Yifan Wang
  • Andrea J Bernhardy
  • Cristina Cruz
  • John J Krais
  • Joseph Nacson
  • Emmanuelle Nicolas
  • Suraj Peri
  • Hanneke van der Gulden
  • Ingrid van der Heijden
  • Shane W O'Brien
  • Yong Zhang
  • Maribel I Harrell
  • Shawn F Johnson
  • Francisco J Candido Dos Reis
  • Paul D P Pharoah
  • Beth Karlan
  • Charlie Gourley
  • Diether Lambrechts
  • Georgia Chenevix-Trench
  • Håkan Olsson
  • Javier J Benitez
  • Mark H Greene
  • Martin Gore
  • Robert Nussbaum
  • Siegal Sadetzki
  • Simon A Gayther
  • Susanne K Kjaer
  • Alan D D'Andrea
  • Geoffrey I Shapiro
  • David L Wiest
  • Denise C Connolly
  • Mary B Daly
  • Elizabeth M Swisher
  • Peter Bouwman
  • Jos Jonkers
  • Judith Balmaña
  • Violeta Serra
  • Neil Johnson
  • kConFab Investigators
Vis graf over relationer

Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this study, we investigated the impact of mutations on BRCA1 isoform expression and therapeutic response. Cancer cell lines and tumors harboring mutations in exon 11 of BRCA1 express a BRCA1-Δ11q splice variant lacking the majority of exon 11. The introduction of frameshift mutations to exon 11 resulted in nonsense-mediated mRNA decay of full-length, but not the BRCA1-Δ11q isoform. CRISPR/Cas9 gene editing as well as overexpression experiments revealed that the BRCA1-Δ11q protein was capable of promoting partial PARPi and cisplatin resistance relative to full-length BRCA1, both in vitro and in vivo Furthermore, spliceosome inhibitors reduced BRCA1-Δ11q levels and sensitized cells carrying exon 11 mutations to PARPi treatment. Taken together, our results provided evidence that cancer cells employ a strategy to remove deleterious germline BRCA1 mutations through alternative mRNA splicing, giving rise to isoforms that retain residual activity and contribute to therapeutic resistance. Cancer Res; 76(9); 2778-90. ©2016 AACR.

OriginalsprogEngelsk
TidsskriftCancer Research
Vol/bind76
Udgave nummer9
Sider (fra-til)2778-90
Antal sider13
ISSN0008-5472
DOI
StatusUdgivet - 1 maj 2016

ID: 49569260